Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

ChemoCentryx Reports Publication Of Positive Phase 2 Data With CCX354

ChemoCentryx Inc. (CCXI: Quote) announced the peer-reviewed publication of positive data from its Phase 2 CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis or RA. The findings showed that CCX354 was generally well tolerated by patients with RA.

Measurement of evidence of clinical activity included the ACR20 response at Week 12 in patients who met trial inclusion criteria at the start of dosing: The response was 56% in patients receiving 200 mg CCX354 once daily, versus 44% in patients receiving 100 mg twice daily and 30% in patients receiving placebo. ACR20 is a standard measure of improvement in tender and swollen joint counts. The difference between 200 mg once daily and placebo was statistically significant.

Also, the data indicated that CCX354 treatment reduced markers of bone turnover, supporting the previously documented role of CCR1 in osteoclast maturation and migration.

"Results from the CARAT-2 study have demonstrated clinical proof-of-concept of CCR1 inhibition in the treatment of RA," stated Thomas Schall, President and Chief Executive of ChemoCentryx.

Register
To receive FREE breaking news email alerts for ChemoCentryx Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.